Skip to main content
TipRanks
Go Ultimate75% OFF

Phio Pharmaceuticals (44R1) Drug Pipeline

3 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ph-762Squamous Cell Carcinoma Of The Skin, Malignant Melanoma Of Skin, Merkel Cell Carcinoma Of SkinPhase IRecruitingIntratumoral PH-762 for Cutaneous CarcinomaAug 22, 2023
Low Dose Il-2, Dp Cd8 Til, Dp Cd8 Til KdUrogenital Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Gynecologic Cancer, HnsccPhase IActive Not RecruitingAdoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid TumorsMay 12, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Phio Pharmaceuticals (DE:44R1) have in its pipeline
Phio Pharmaceuticals DE:44R1 is currently developing the following drugs: Ph-762, Low Dose Il-2, Dp Cd8 Til, Dp Cd8 Til Kd. These drug candidates are in various stages of clinical development as the company works toward FDA approval.